Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More
